Company Overview and News

 
Share buying increased during quiet 3-day week in Hong Kong

2017-05-07 scmp
Shanghai Industrial Urban Development Group, HC International and Minth Group all made sizable purchases in the week ended May 5

 
DC Holdings Initiates the Establishment of China Healthcare Big Data Development Co., Ltd to Construct the Healthcare Big Data Ecosystem

2017-04-28 prnewswire
HONG KONG, April 28, 2017 /PRNewswire/ -- Digital China Holdings Limited ("DC Holdings" or the "Group"; stock code: 00861.HK, 910861.TW), China's largest integrated IT service provider, is pleased to announce that the signing ceremony of China Healthcare Big Data Development Co., Ltd. (CHBDDC) was held in Beijing. DC Holdings initiated the establishment of CHBDDC. Guo Wei, Chairman of DC Holdings, and Jin Xiaotao, Deputy Director of National Health and Family Planning Commission, delivered speech at the ceremony.

 
Hong Kong firms and insiders pick up shares following price gains

2016-10-02 scmp
The buying rose after falling for two straight weeks while the selling among directors remained high based on filings on the Hong Kong stock exchange in the last week of September. A total of 26 companies recorded 104 purchases worth HK$103 million versus 18 firms with 67 disposals worth HK$257 million.

 
Global Sources: Major Concerns With One Of The Oldest China Reverse Takeovers

2016-09-18 seekingalpha
GSOL claims more than 1 million active international buyers use the site from more than 240 countries and territories to connect with suppliers. In mainland China, the Company has a network of more than 40 office locations (60 global locations) and a community of nearly 3 million registered online users and magazine readers of its Chinese-language media. GSOL delivers information on over 5.7 million products and more than 262,000 suppliers annually through 14 online marketplaces, 13 monthly print and 18 digital magazines, over 90 sourcing research reports and 73 specialized trade shows a year across nine cities.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...